MHRA renews EAMS scientific opinion for Puldysa in DMD by Anna Smith | Jun 24, 2019 | News | 0 The drug has been available in the UK through EAMS since June 2017. Read More
Santhera submits MAA to EMA for Puldysa by Anna Smith | May 28, 2019 | News | 0 The company is seeking conditional marketing authorisation (CMA) for patients with DMD who are not using glucocorticoids. Read More
Novo Nordisk files for EU approval of Ozempic in type II diabetes by Anna Smith | Apr 26, 2019 | News | 0 Patients treated with oral semaglutide demonstrated greater HbA1c reductions and weight loss. Read More
EMA confirms path for Diurnal’s Chronocort despite trial failure by Anna Smith | Apr 12, 2019 | News | 0 The company is on track to submit a Marketing Authorisation Application in the fourth quarter of 2019. Read More